We found that targeted PD-1 agonist ImmTAAI molecules are potent inhibitors of effector T cells, offering a promising route to successfully exploit this pathway and generate target cell–specific T cell inhibitors for the treatment of autoimmune diseases. Here, PDCD1 is linked to autoimmune disease.